Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults

Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

NCT01562444 ·Status: COMPLETED ·Phase: PHASE4

Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

NCT04648241 ·Status: COMPLETED ·Phase: PHASE3

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.

NCT00161772 ·Status: COMPLETED ·Phase: PHASE2

Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children

NCT00163618 ·Status: COMPLETED

New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly

NCT02318069 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children

NCT00840801 ·Status: COMPLETED ·Phase: PHASE3

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

NCT00718666 ·Status: COMPLETED ·Phase: PHASE2

Humoral Response to Tick-borne Encephalitis Vaccine in Elderly

NCT01361776 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults

NCT00118924 ·Status: COMPLETED ·Phase: PHASE1

Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)

NCT01031537 ·Status: TERMINATED ·Phase: PHASE2

Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years

NCT00161746 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

NCT00322335 ·Status: COMPLETED ·Phase: PHASE3

Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib

NCT00332566 ·Status: COMPLETED ·Phase: PHASE3

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

NCT00454987 ·Status: COMPLETED ·Phase: PHASE4

Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™

NCT00654901 ·Status: COMPLETED ·Phase: PHASE3

Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

NCT00136604 ·Status: COMPLETED ·Phase: PHASE3

Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine

NCT00146835 ·Status: COMPLETED

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

NCT00595309 ·Status: COMPLETED ·Phase: PHASE3

Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

NCT00595270 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™

NCT00534833 ·Status: COMPLETED ·Phase: PHASE3

Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children

NCT02139228 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants

NCT00303316 ·Status: COMPLETED ·Phase: PHASE3

6-year Antibody Check After Third Vaccination Against Japanese Encephalitis

NCT02039440 ·Status: COMPLETED ·Phase: PHASE4

Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination

NCT01983540 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants

NCT01098474 ·Status: COMPLETED ·Phase: PHASE2